amyloid positron emission tomography (amyloid PET)
Jump to navigation
Jump to search
Indications
- evaluation of Alzheimer's disease (AD)
- sensitivity > specificity
- bilateral parietal hypometabolism
Clinical significance
- both amyloid-positive & amyloid-negative results associated with changes in diagnosis & treatment[1]
- in both patients with dementia & those with mild cognitive impairment[3]
- early amyloid PET improves confidence in diagnosis[4]
- amyloid PET using [18F]-florbetapir not cost-effective[2]
- no difference in change in healthcare utilization between patients with PET scans showing elevated vs non-elevated beta-amyloid[6]
Procedure
Notes
- there is also a TAU-PET for AD
- CMS is proposing to end restrictions on how many amyloid PET scans Alzheimer's disease patients can receive[5]
More general terms
More specific terms
References
- ↑ 1.0 1.1 George J, Solomon HA, Caputo D Amyloid PET Changes Diagnosis, Treatment. Dutch study may boost prospects for insurance, Medicare coverage. MedPage Today. June 11, 2018 https://www.medpagetoday.com/neurology/alzheimersdisease/73412
de Wilde A, van der Flier WM, Pelkmans W et al Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. JAMA Neurol. 2018 Jun 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29889941
Salloway S Improving Evaluation of Patients With Cognitive Impairment With Amyloid Positron Emission Tomography. JAMA Neurol. 2018 Jun 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29889928 - ↑ 2.0 2.1 Boccardi M, Altomare D, Ferrari C et al. Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]- Florbetapir (INDIA-FBP) study. JAMA Neurol 2016 Oct 31; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27802513 <Internet> http://jamanetwork.com/journals/jamaneurology/article-abstract/2578330
- ↑ 3.0 3.1 Rabinovici GD, Gatsonis C, Apgar C et al Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019;321(13):1286-1294 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30938796 https://jamanetwork.com/journals/jama/fullarticle/2729371
Jack CR Jr, Petersen RC. Amyloid PET and Changes in Clinical Management for Patients With Cognitive Impairment. JAMA. 2019;321(13):1258-1260 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30938781 https://jamanetwork.com/journals/jama/fullarticle/2729351 - ↑ 4.0 4.1 Altomare D et al. Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: The AMYPAD-DPMS randomized clinical trial. JAMA Neurol 2023 Jun 1; 80:548. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37155177 PMCID: PMC10167601 Free PMC article https://jamanetwork.com/journals/jamaneurology/fullarticle/2804755
- ↑ 5.0 5.1 CMS.gov. July 2023 Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=308
- ↑ 6.0 6.1 Jutkowitz E, Shewmaker P, Ford CB et al Association between results of an amyloid PET scan and healthcare utilization in individuals with cognitive impairment. J Am Geriatr Soc. 2024 Mar;72(3):707-717 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38069618 https://agsjournals.onlinelibrary.wiley.com/doi/abs/10.1111/jgs.18696